VYGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Voyager Therapeutics Inc (VYGR) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators show a bearish trend, insider selling is increasing, and financial performance is weak. While there is some positive sentiment from analysts with an increased price target, the lack of recent news, poor revenue growth, and no significant trading signals suggest holding off on investment for now.
The MACD is negative and expanding (-0.0337), RSI is neutral at 31.515, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Support levels are at 3.429 and 3.257, with resistance at 3.987 and 4.159. The stock is currently trading below its pivot point of 3.708, indicating a bearish trend.
Morgan Stanley raised the price target from $25 to $39, citing potential benefits from the Space Superiority Executive Order. Gross margin remains strong at 100%.
The stock has a 50% chance of declining in the short term (-0.61% in the next day, -1.99% in the next week). No recent news or congress trading data available.
In Q3 2025, revenue dropped by 45.73% YoY to $13,365,000. Net income improved but remains negative at -$27,892,000 (up 208.40% YoY). EPS increased to -0.47 (up 193.75% YoY). Gross margin remains at 100%, unchanged YoY.
Morgan Stanley raised the price target to $39 from $25 but maintained an Equal Weight rating, reflecting cautious optimism. Analysts are monitoring the impact of the Space Superiority Executive Order on the company's opportunities.
